Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLINASDAQ:LNTHNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$16.00-3.9%$14.66$10.57▼$33.33$2.31B1.581.08 million shs36,803 shsLNTHLantheus$105.66+1.3%$98.78$65.89▼$126.89$7.20B0.2947,644 shs30,708 shsROIVRoivant Sciences$11.64+0.2%$10.38$8.73▼$13.06$8.31B1.255.46 million shs195,424 shsRVMDRevolution Medicines$40.06-0.8%$37.36$29.17▼$62.40$7.43B1.371.44 million shs31,069 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+0.91%+11.90%+22.43%-29.39%+7.84%LNTHLantheus+0.37%+3.10%+6.91%+12.45%+56.81%ROIVRoivant Sciences+2.92%+8.19%+15.16%+2.20%+6.61%RVMDRevolution Medicines-0.71%+7.71%+14.20%-6.25%+8.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNLIDenali Therapeutics4.1568 of 5 stars4.50.00.04.73.61.70.0LNTHLantheus3.9711 of 5 stars2.51.00.04.23.52.51.9ROIVRoivant Sciences2.1666 of 5 stars3.51.00.00.03.52.50.0RVMDRevolution Medicines3.762 of 5 stars3.50.00.04.73.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 3.06Buy$37.57134.89% UpsideLNTHLantheus 3.00Buy$129.4322.50% UpsideROIVRoivant Sciences 3.00Buy$17.5050.29% UpsideRVMDRevolution Medicines 3.00Buy$66.6766.44% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, ROIV, RVMD, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/24/2025DNLIDenali TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/10/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.003/10/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.003/7/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.00 ➝ $33.003/5/2025DNLIDenali TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $35.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M7.03N/AN/A$7.42 per share2.16LNTHLantheus$1.53B4.72$8.82 per share11.98$11.91 per share8.87ROIVRoivant Sciences$122.59M67.78N/AN/A$7.76 per share1.50RVMDRevolution Medicines$742K10,036.04N/AN/A$11.09 per share3.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$145.22M-$2.57N/AN/AN/AN/A-32.94%-30.04%5/6/2025 (Estimated)LNTHLantheus$326.66M$4.3717.5016.74N/A28.57%44.29%23.52%5/7/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/6/2025 (Estimated)Latest DNLI, ROIV, RVMD, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/14/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/7/2025Q1 2025LNTHLantheus$1.64N/AN/AN/A$377.37 millionN/A5/6/2025Q1 2025DNLIDenali Therapeutics-$0.73N/AN/AN/A$3.24 millionN/A2/27/2025Q4 2024DNLIDenali Therapeutics-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali TherapeuticsN/A9.989.98LNTHLantheusN/A1.651.56ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%LNTHLantheus99.06%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics7.90%LNTHLantheus1.50%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430145.24 million132.55 millionOptionableLNTHLantheus70068.48 million68.48 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250185.91 million154.76 millionOptionableDNLI, ROIV, RVMD, and LNTH HeadlinesRecent News About These CompaniesRevolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025April 30 at 4:15 PM | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Shares Up 5.8% - Should You Buy?April 30 at 1:33 PM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given "Outperform" Rating at WedbushApril 30 at 10:33 AM | marketbeat.comHsbc Holdings PLC Trims Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 30 at 5:09 AM | marketbeat.comWedbush Reiterates Outperform Rating for Revolution Medicines (NASDAQ:RVMD)April 30 at 3:33 AM | americanbankingnews.comArtia Global Partners LP Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 7:00 AM | marketbeat.comWhy Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.47%April 29 at 6:39 AM | aaii.comAquatic Capital Management LLC Buys 78,605 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:35 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $10 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:24 AM | marketbeat.comTower Research Capital LLC TRC Has $808,000 Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 4:46 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Decheng Capital LLC's 8th Largest PositionApril 28 at 7:18 AM | marketbeat.comOxford Asset Management LLP Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 7:01 AM | marketbeat.comGhisallo Capital Management LLC Makes New $11.25 Million Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 6:37 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Adage Capital Partners GP L.L.C.April 28 at 5:37 AM | marketbeat.com7,306 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Syon Capital LLCApril 28 at 5:36 AM | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 552,657 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 5:08 AM | marketbeat.comNatixis Sells 83,624 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 4:35 AM | marketbeat.comInvesco Ltd. Has $5.15 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 3:33 AM | marketbeat.comRevolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual MeetingApril 27, 2025 | globenewswire.comLord Abbett & CO. LLC Has $86.55 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 27, 2025 | marketbeat.comMetLife Investment Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)April 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, ROIV, RVMD, and LNTH Company DescriptionsDenali Therapeutics NASDAQ:DNLI$16.00 -0.66 (-3.93%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Lantheus NASDAQ:LNTH$105.66 +1.32 (+1.26%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$11.64 +0.02 (+0.21%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$40.06 -0.33 (-0.80%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hershey Hits the Sweet Spot for Defensive Investors AMD Stock Signals Strong Buy Ahead of Earnings Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
